143 related articles for article (PubMed ID: 11378378)
41. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
Charrier C; Bertrand P; Gesson JP; Roche J
Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
[TBL] [Abstract][Full Text] [Related]
42. Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression.
Ailenberg M; Silverman M
Biochem Biophys Res Commun; 2002 Oct; 298(1):110-5. PubMed ID: 12379227
[TBL] [Abstract][Full Text] [Related]
43. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
Nuti E; Orlandini E; Nencetti S; Rossello A; Innocenti A; Scozzafava A; Supuran CT
Bioorg Med Chem; 2007 Mar; 15(6):2298-311. PubMed ID: 17276072
[TBL] [Abstract][Full Text] [Related]
44. Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.
Burns DM; Li YL; Shi E; He C; Xu M; Zhuo J; Zhang C; Qian DQ; Li Y; Wynn R; Covington MB; Katiyar K; Marando CA; Fridman JS; Scherle P; Friedman S; Metcalf B; Yao W
Bioorg Med Chem Lett; 2009 Jul; 19(13):3525-30. PubMed ID: 19457660
[TBL] [Abstract][Full Text] [Related]
45. MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.
Marcq V; Mirand C; Decarme M; Emonard H; Hornebeck W
Bioorg Med Chem Lett; 2003 Sep; 13(17):2843-6. PubMed ID: 14611841
[TBL] [Abstract][Full Text] [Related]
46. MMP-2 selectivity in hydroxamate-type inhibitors.
Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B
Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051
[TBL] [Abstract][Full Text] [Related]
47. Rapid assembly of matrix metalloprotease inhibitors using click chemistry.
Wang J; Uttamchandani M; Li J; Hu M; Yao SQ
Org Lett; 2006 Aug; 8(17):3821-4. PubMed ID: 16898826
[TBL] [Abstract][Full Text] [Related]
48. The interaction of metal ions and Marimastat with matrix metalloproteinase 9.
Underwood CK; Min D; Lyons JG; Hambley TW
J Inorg Biochem; 2003 Jun; 95(2-3):165-70. PubMed ID: 12763661
[TBL] [Abstract][Full Text] [Related]
49. Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.
Angibaud P; Arts J; Van Emelen K; Poncelet V; Pilatte I; Roux B; Van Brandt S; Verdonck M; De Winter H; Ten Holte P; Marien A; Floren W; Janssens B; Van Dun J; Aerts A; Van Gompel J; Gaurrand S; Queguiner L; Argoullon JM; Van Hijfte L; Freyne E; Janicot M
Eur J Med Chem; 2005 Jun; 40(6):597-606. PubMed ID: 15922843
[TBL] [Abstract][Full Text] [Related]
50. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
[TBL] [Abstract][Full Text] [Related]
51. Structure-activity relationship studies of novel oxygen-incorporated SAHA analogues.
Kim SA; Jin YL; Kim HS
Arch Pharm Res; 2009 Jan; 32(1):15-21. PubMed ID: 19183872
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and Anticancer Activity of Novel Actinonin Derivatives as HsPDF Inhibitors.
Hu L; Cai X; Dong S; Zhen Y; Hu J; Wang S; Jiang J; Huang J; Han Y; Qian Y; Yuan Y; Hu W
J Med Chem; 2020 Jul; 63(13):6959-6978. PubMed ID: 32551649
[TBL] [Abstract][Full Text] [Related]
53. Matrix metalloproteinases: biologic activity and clinical implications.
Nelson AR; Fingleton B; Rothenberg ML; Matrisian LM
J Clin Oncol; 2000 Mar; 18(5):1135-49. PubMed ID: 10694567
[TBL] [Abstract][Full Text] [Related]
54. Potent homophthalimide-type inhibitors of B16F10/L5 mouse melanoma cell invasion.
Kagechika H; Komoda M; Fujimoto Y; Koiso Y; Takayama H; Kadoya S; Miyata K; Kato F; Kato M; Hashimoto Y
Biol Pharm Bull; 1999 Sep; 22(9):1010-2. PubMed ID: 10513635
[TBL] [Abstract][Full Text] [Related]
55. Conversion of potent MMP inhibitors into selective TACE inhibitors.
Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
[TBL] [Abstract][Full Text] [Related]
56. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Richon VM; Zhou X; Rifkind RA; Marks PA
Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
[No Abstract] [Full Text] [Related]
57. Hydroxamic acids as pharmacological agents.
Muri EM; Nieto MJ; Sindelar RD; Williamson JS
Curr Med Chem; 2002 Sep; 9(17):1631-53. PubMed ID: 12171558
[TBL] [Abstract][Full Text] [Related]
58. Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family.
Zapico JM; Puckowska A; Filipiak K; Coderch C; de Pascual-Teresa B; Ramos A
Org Biomol Chem; 2015 Jan; 13(1):142-56. PubMed ID: 25348733
[TBL] [Abstract][Full Text] [Related]
59. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
Woo SH; Frechette S; Abou Khalil E; Bouchain G; Vaisburg A; Bernstein N; Moradei O; Leit S; Allan M; Fournel M; Trachy-Bourget MC; Li Z; Besterman JM; Delorme D
J Med Chem; 2002 Jun; 45(13):2877-85. PubMed ID: 12061890
[TBL] [Abstract][Full Text] [Related]
60. Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.
Becker DP; Barta TE; Bedell LJ; Boehm TL; Bond BR; Carroll J; Carron CP; Decrescenzo GA; Easton AM; Freskos JN; Funckes-Shippy CL; Heron M; Hockerman S; Howard CP; Kiefer JR; Li MH; Mathis KJ; McDonald JJ; Mehta PP; Munie GE; Sunyer T; Swearingen CA; Villamil CI; Welsch D; Williams JM; Yu Y; Yao J
J Med Chem; 2010 Sep; 53(18):6653-80. PubMed ID: 20726512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
